Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tango Therapeutics, Inc.

TNGX ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$23.35

▼ -2.26%

Market Cap $3.94B · Vol 685.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.94B

Mid Cap

Div Yield

N/A

EPS Growth

-62.74%

YoY

RSI (14)

37.23

Momentum

Beta

1.18

vs Market

52W High

$34.37

32.06% below

52W Low

$6.69

249.03% above

Volume

685.01K

Avg 760.75K

P/B

3.48

Price-to-book

ROE

N/A

Return on equity

Free Float

96.82%

Public shares

Shariah Compliance8 STANDARDS

✗ Tango Therapeutics, Inc. (TNGX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TNGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.71%

-8.79%

-27.39%

+30.59%

YTD

+163.54%

+217.69%

+174.38%

+37.43%

Financials & Valuation

TTM · Annual

Total Revenue	$62.38M
Net Income	$-101,594,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-178.39%
Net Profit Margin	-162.85%
ROE	N/A
ROA · ROIC	-28.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	16.50
P/B	3.48
P/FCF	N/A
EPS Growth	-62.74%
Outstanding Shares	168.61M

Technical Indicators

50-Day SMA	$26.14
200-Day SMA	$20.09
RSI (14)	37.23
Beta	1.18
52-Week High	$34.37
52-Week Low	$6.69

Volume Today	685.01K
Avg Daily Volume (30D)	760.75K
Relative Volume	0.90x
Volatility (10D)	40.96
Volatility (30D)	48.63
Free Float	96.82%

Analyst Consensus

BUY

Current Price $23.35

Mean Target $45.10

52W Low$6.69 52W High$34.37

Current

Target

$6.69 $34.37

Current Analyst target

+93.15% upside potential · 12 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00WFDDSK6

ISINUS87583X1090

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.22% ONC BeOne Medicines AG +0.46% 068270.KS Celltrion, Inc. -0.17% MEDP Medpace Holdings, Inc. -0.65% ABVX Abivax SA -4.15%

Company Profile

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.